Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

2.860 +0.140 (+5.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
Via Benzinga
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Via ACCESSWIRE
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Via ACCESSWIRE
BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Via Benzinga
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
Via Benzinga
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
Exposures COVID-19
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on... 
From CureVac
Via AccessWire
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Billionaire Bill Gates Is Betting Against TSLA Stock. Here’s Where He’s Putting His Money Instead.
Earlier this year, it was revealed that Bill Gates had a half a billion dollar short position against TSLA stock. So, what is he bullish on? 
Via InvestorPlace
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Exposures COVID-19
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From CureVac
Via AccessWire
Exposures COVID-19
How To Attend CureVac Q4 2021 Earnings Conference Call
CureVac (NASDAQ:CVAC) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q4 2021 earnings results. How to Attend CureVac (CVAC) Conference Call Follow this link to access the live... 
Via Benzinga
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron... 
From CureVac
Via AccessWire
Exposures COVID-19
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million... 
From CureVac
Via AccessWire
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine... 
From CureVac
Via AccessWire
Exposures COVID-19
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics - CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate... 
From CureVac
Via AccessWire
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad... 
From CureVac
Via AccessWire
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.